Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin
Jacob
J
Department of Internal Medicine F, Tel Aviv Sourasky Medical Center, Israel.
Cabili
Shaltiel
S
Lagziel
Ayala
A
Peretz
Hava
H
D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000925:Anticoagulants / Q000378:metabolism* / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006720:Homozygote; D006801:Humans; D008297:Male; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics* / Q000378:metabolism; D014859:Warfarin / Q000378:metabolism* / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D039181:Steroid 16-alpha-Hydroxylase